drugset / Trial / NCT05305066
Stand UP to Rheumatoid Arthritis (SUPRA)
Recruiting
75 enrolled
Marie Hudson, MD
Lady Davis Institute · collabMcGill University Health Centre/Research Institute of the McGill University Health Centre · collabMontreal General Hospital · collab
RandomizedParallel-groupOpen-labelOther
Summary
Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2028-12-31
- Completion
- 2030-12
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | — |
| Subject | Baricitinib | Small molecule | 2 mg | Oral |
| Subject | Certolizumab | Protein / enzyme biologic | 200 mg | — |
| Subject | Certolizumab | Protein / enzyme biologic | 400 mg | — |
| Subject | Etanercept | Protein / enzyme biologic | 50 mg | — |
| Subject | Golimumab | Monoclonal antibody | 50 mg | — |
| Subject | Sarilumab | Monoclonal antibody | 200 mg | — |
| Subject | Tocilizumab | Monoclonal antibody | 162 mg | — |
| Subject | Tofacitinib | Small molecule | 5 mg | Oral |
| Subject | Upadacitinib | Small molecule | 15 mg | Oral |